Colorectal cancer is one of the most common cancers in the U.S., so last month’s NEJM NordICC Trial stirred up enormous media attention and controversy about the optimal strategies for colon cancer screening. Douglas Corley, MD, PhD, a leading cancer epidemiologist and clinical gastroenterologist, will bring us up-to-date on the newest colorectal cancer screening trials, explain potential population-level effects of different screening methods, and tell us how we might decrease disparities in colorectal cancer incidence and mortality.
Speaker:
Douglas Corley, MD, PhD, is a clinical professor in the Division of Gastroenterology at UCSF and a cancer epidemiologist and gastroenterologist at Kaiser Permanente Northern California (KPNC). He directs the Delivery Science and Applied Research program for The Permanente Medical Group, which coordinates rapid cycle, clinician-led research and implementation across KPNC. He was the national steering committee chair for the NCI Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium, just completed a term as editor-in-chief of the specialty’s leading journal, Gastroenterology, and co-led the Screening and Prevention Working Group for the NCI’s Cancer Research Network.
Note: Closed captions will be available within 48-72 hours after posting.
Program
Bob Wachter: Introduction
00:02:20-00:52:12 – Douglas Corley, MD, PhD, (Professor, Division of Gastroenterology at UCSF Health)
00:52:14-01:00:49 Q&A
See previous Medical Grand Rounds:
• November 3: A Fireside Chat with Kirsten Bibbins-Domingo, Editor-in-Chief of JAMA
[ Ссылка ]
• October 27: The Current & Future State of COVID: Updates from the Infectious Diseases Society of America Meeting
[ Ссылка ]
• October 20: Shock Teams: The Jaws of Life for Cardiogenic Shock
[ Ссылка ]
• October 13: Clinical Problem Solving with Lisa Winston
[ Ссылка ]
See all UCSF Covid-19 grand rounds, which have been viewed over 3M times, at [ Ссылка ].
